ATLANTIC HEALTH GUIDELINES FOR ANTICOAGULANT, ANTIPLATELET, AND THROMBOLYTIC REVERSAL IN ADULT PATIENTS
|
|
- Damon Owen
- 6 years ago
- Views:
Transcription
1 ATLANTIC HEALTH GUIDELINES FOR ANTICOAGULANT, ANTIPLATELET, THROMBOLYTIC REVERSAL IN ADULT PATIENTS Several of the below interventions are based on low-level evidence and are intended as suggestions only. This guideline should not replace though clinical judgement. Warnings Regarding Use of Prothrombin Complex Concentrates (PCCs) : Kcentra, Profilnine SD, FEIBA NF 1. PCC use increases risk of thrombotic events! 2. Not recommended f: A. Reversal of anticoagulation pri to elective, non-urgent surgical interventions 3. Not studied in/ limited data in: A. Patients with a thromboembolic event, myocardial infarction, disseminated intravascular coagulation, cerebral vascular accident, transient ischemic attack, unstable angina pectis, severe peripheral vascular disease within the pri 3 months. B. F patients with ICH: Glasgow coma sce (GCS) < 7; intracerebral hematoma volume > 30cc as assessed by ABC/2; f subdural hematomas: maximum thickness 10 mm, midline shift 5 mm; f subarachnoid hemrhage: any evidence of hydrocephalus; infratential ICH location; epidural hematomas; intraventricular extension of hemrhage; modified Rankin sce (mrs) of >3 pri to ICH C. Known histy of antiphospholipid antibody syndrome lupus anticoagulant antibodies D. Known inhibits to coagulation facts II, VII, IX, X; hereditary protein C protein S deficiency; heparin-induced, type II thrombocytopenia E. Pregnant breast-feeding women Agents Effect on coagulation doses with al direct thrombin inhibits DIRECT THROMBIN INHIBITORS (DTIs) IV: Argatroban : Hepatic impairment: 181 Bivalirudin (Angiomax) CrCl 90: 25 ; CrCl 10-29: 57 ; Dialysis dependent patients (off dialysis): 3.5 hours PO: Dabigatran (Pradaxa) CrCl > 80: hours CrCl 50-79: 16.6 hours CrCl 30-49: 18.7 hours CrCl < 30: 27.5 hours IV DTIs can falsely elevate the INR level. aptt Thrombin Time (TT) most useful f determining if any dabigatran is present Ecarin Clotting Time (ECT) the kits have not been standardized Reversal Consider holding discontinue agent if clinically appropriate Consider activated charcoal if ingestion less than 2 hours (dabigatran) Blood product transfusion f hemodynamic Consider hemodialysis (dabigatran and bivalirudin) Maj/Life-threatening (F IV DTIs there are no clinical studies but may use recommendations below) (preferred) Feiba NF 20 units/kg IV x 1 dose over 10. If no improvement in after first dose, may consider second dose of 20 units/kg after 30 OR Kcentra 50 units/kg IV at a rate not to exceed 8.4 ml/min (max 5,000 units) Round to the nearest whole vial size If Suspected Documented HIT: Profilnine SD 50 units/kg IV at a rate not Comments There are no specific antidotes f direct thrombin inhibits documented HIT; it give PCC and rfviia together due to high risk of thrombosis
2 FACTOR XA INHIBITORS Fondaparinux (Arixtra) hours in nmal renal function Rivaroxaban (Xarelto) CrCl > 80: 5-9hours CrCl 50-79: 9.7hours CrCl 30-49: 9 hours CrCl < 30: 9.5hours Apixaban (Eliquis) CrCl > 80: 8-15hours CrCl 50-79: 14.6 CrCl 30-49: 17.6 CrCl < 30: 17.3 validated with dabigatran (Not available at AHS) doses (most sensitive f rivaroxaban/apix aban) aptt at doses Consider holding discontinue agent if clinically appropriate Consider activated charcoal if ingestion less than 8 hours (rivaroxaban) less than 3 hours (apixaban) Blood product transfusion f hemodynamic Hemodialysis (fondaparinux) increases clearance of fondaparinux by 20% Maj/Life-threatening (preferred) Kcentra 50 units/kg IV at a rate not to exceed 8.4 ml/min (max 5,000 units) Round to the nearest whole vial size If Suspected Documented HIT: Profilnine SD 50 units/kg IV at a rate not There are no specific antidotes f fact Xa inhibits give PCC and rfviia together due to high risk of thrombosis Hemodialysis not recommended f rivaroxaban/ apixaban documented HIT; it HEPARIN 1-2 hours LMWHs Enoxaparin IV: 2-4 hours Subcutaneous: 8 hours aptt Heparin Bolus Heparin Subcutaneous Time since Recommendation heparin Less than 30 Protamine 1 mg f every 100 units of heparin received Protamine 0.5 mg f every 100 units of heparin received Greater than 60 Protamine 0.25 mg f every 100 units of heparin received Heparin Infusion Protamine 1 mg f every 100 units of heparin received in previous 2-3 hours Example: A patient is receiving a heparin infusion of 1,000 units/hour would require a protamine dose of about 25 mg Time since dose Less than equal to 8 hours Greater than 8 hours Recommendation Protamine 1 mg f every 1 mg of received Protamine 0.5 mg f every 1 mg of received Protamine 1 mg will neutralize the effects of approximately 100 units of heparin Protamine administration rate should not exceed 5 mg/min Do not exceed 50 mg in any 10 minute period 100 mg in 2 hours Protamine neutralizes the anti-iia activity, but has incomplete neutralization of anti-xa activity Protamine administration rate should not exceed 5 mg/min Do not exceed 50 mg in any 10 minute period 100 mg in 2 hours
3 WARFARIN 36 hours doses Non-Maj/ Non-Life-Threatening Bleeding INR Recommendation INR me than Hold warfarin until therapeutic range INR returns to goal but less than 4.5 If urgent surgery: No significant Vitamin K 2.5 mg PO ( 1 mg IV by INR 4.5 to 10 No significant INR greater than 10 No significant ( min ) Hold warfarin until INR returns to goal Omit dose and give vitamin K mg PO If urgent surgery: Vitamin K 2.5 mg PO ( 1 mg IV by Hold warfarin and give: Vitamin K mg PO ( 1 mg IV by Blood product transfusion f hemodynamic May repeat Vitamin K IV after hours f persistent INR elevation Vitamin K administered subcutaneously has not been shown to have any effect on decreasing INR Intravenous administration of Vitamin K should not exceed a rate of 1 mg/min; use filter needle and dilute to 50 ml NSS DO NOT give Vitamin K as IV Push IM documented HIT; it Note INR cutoff at Atlantic Health lab is >7, if INR is repted >7 it is recommended to err on the side of caution Maj/Life-threatening at any INR Vitamin K 10mg IV slow infusion (infused no faster than 1mg/min) PLUS (preferred) Kcentra based on INR value: INR between 2 to 25 units/kg 4 (max 2,500 units) INR 4 to 6: INR greater than 6 35 units/kg (max 3,500 units) 50 units/kg (max 5,000 units) Round to the nearest whole vial size If Suspected Documented HIT: Profilnine SD 50 units/kg IV at a rate not FFP 15-30mL/kg
4 ASPIRIN CLOPIDOGREL 8 hours ~5 days f platelet recovery PRASUGREL 7 hours TICAGRELOR ~9 hours GP IIb-IIIa Abciximab(Reopro ) Eptifibatide (Integrilin ) Irreversible platelet inhibition 5-7 days needed f platelet recovery (aspirin, clopidogrel, prasugrel) Ticagrel is a reversible platelet inhibit 72 hours f platelet recovery Platelet transfusions often needed to attenuate Consider DDAVP 0.3mcg/kg IV x 1 over min Due to a relative sht half-life, supptive care and discontinuation of GP IIb-IIIa inhibits are primary treatment Platelet transfusions often needed to attenuate Tolerance to DDAVP may develop with repeat doses. Note DDAVP has the potential to induce hyponatremia and/ seizure Hemodialysis (f life threatening associated with eptifibatide) THROMBOLYTICS IV: Alteplase Note: About 50% cleared ~ 5 after infusion terminated; About 80% cleared in 10 : : May decrease fibrinogen level Clot lysis releases D- Dimers, which may exert antiplatelet effect Consider DDAVP 0.3mcg/kg IV x 1 over min Terminate infusion (note: 80% of alteplase cleared in 10 from plasma) Blood product transfusion f hemodynamic (PRBCs, cryoprecipitate, platelets, FFP) Guidelines do not suppt specific therapy f of thrombolytic associated There are no antidotes f thrombolytics give PCC rfviia due to lack of evidence and thrombotic risk Tenecteplase biphasic: initial ; terminal PT= prothrombin time; INR = International Nmalized Ratio; aptt=activated partial thromboplastin time; AHS=Atlantic Health System; CrCl=creatinine clearance, repted in ml/minute; PCC=partial complex concentrates; rfviia=recombinant Fact VIIa; HIT=heparin induced thrombocytopenia; LMWH= low molecular weight heparin; FFP=fresh frozen plasma; PRBC=packed red blood cells FEIBA NF is a PCC product that contains Facts II, IX, and X, mainly non-activated, and Fact VII mainly in the activated fm Kcentra is a 4-fact PCC product that contains Facts II, VII, IX, X Profilnine SD is a 3-fact product that contains Facts II, IX, X References 1. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis. CHEST 2012 f Antithrombotic and Thrombolytic Therapy. CHEST 2012;141:24S-43S 2. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis. CHEST 2012 f Antithrombotic and Thrombolytic Therapy. CHEST 2012;141:44S-87S 3. Evidence-based of anticoagulant therapy. Antithrombotic Therapy and Prevention of Thrombosis. CHEST 2012 f Antithrombotic and Thrombolytic Therapy. CHEST 2012;141:152S177S
5 4. Lemon SJ, Crannage AJ. Pharmacologic anticoagulation reversal in emergency department. Adv Emerg Nurs J 2011;33: Kalus JS. Pharmacologic interventions f reversing the effects of al anticoagulants. Am J Health Syst Pharm 2013;70:S Khoo TL et al. The use of FEIBA( ) in the crection of coagulation abnmalities induced by dabigatran. Int J Lab Hematol [Epub ahead of print] 7. Daeger W et al. Reversing dabigatran with FEIBA in a patient with transseptal perfation during cardiac ablation. Crit Care Med. 2011;39(12), Abstract 8. Marlu R et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. J Thromb Haemost. 2012;108(2): Eerenberg ES et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011;124(14): Eikelboom JW, Hirsh J. Bleeding and of. Eur Heart J Suppl. 2006;8:G Peter FW, Benkovic C, Muehlberger T, et al. Effects of desmopressin on thrombogenesis in aspirininduced platelet dysfunction. Br J Haematol. 2002;117(3): Tcheng JE. Clinical challenges of platelet glycoprotein IIb/IIIa recept inhibit therapy: Bleeding, reversal, thrombocytopenia, and retreatment. Am Heart J. 2000;139:S38-S Ranucci M, Nano G, Pazzaglia A, et al. Platelet mapping and desmopressin reversal of platelet inhibition during emergency carotid endarterectomy. J Cardiothac Vasc Anesth.2007;21(6): Epub 2007 Jul Pernod G et al. Reversal of anticoagulant properties of antixa and antiiia anticoagulant by non specific haemostatic drugs: an ex vivo study in healthy voluteers. J Thromb Haemost 2011;9: Hursting MJ et al. Transitioning from argatroban to warfarin therapy in patients with heparin- induced thrombocytopenia. Clin Appl Thromb Hemost Jul;11(3): Becker JC, Hursting MJ, Joffrion JL, et al. Clinical effect of concurrent warfarin on the efficacy of argatroban therapy in heparin-induced thrombocytopenia (abstract). Blood 1997;90(Suppl):110b. 17. Nutescu EA. New approaches to reversing al anticoagulant therapy. Am J Health-Syst Pharm. 2013; 70(Suppl 1):S French KF et al. Treatment of intracerebral hemrhage with tranexemic acid after thrombolysis with tissue plasminogen activat. Neurocrit Care 2012;17: Goldstin JN et al. Management of thrombolysis-associated symptomatic intracerebral hemrhage. Arch Neurol 2010;67(8): Approved by Overlook Pharmacy and Therapeutics Committee on October 8 th, 2013 Approved by Mristown Pharmacy and Therapeutics Committee on October 10 th, 2013 Approved by Newton Pharmacy and Therapeutics Committee on September 3 rd, 2013
Adult Reversal of Anticoagulation and Anti-platelet Agents for Life- Threatening Bleeding or Emergency Surgery Protocol
Adult Reversal of Anticoagulation and Anti-platelet Agents for Life- Threatening Bleeding or Emergency Surgery Protocol Page Platelet Inhibitors 2 Aspirin, Clopidogrel (Plavix), Prasugrel (Effient) & Ticagrelor
More informationADVOCATE HEALTHCARE GUIDELINE FOR ANTITHROMBOTIC REVERSAL
Minimal clinical evidence exists to support the efficacy of nonspecific procoagulant therapies that promote thrombin formation and antifibrinolytics in the setting of antithrombotic-related bleeding. Hemostatic
More informationADMINISTRATIVE CLINICAL Page 1 of 6
ADMINISTRATIVE CLINICAL Page 1 of 6 Anticoagulant Guidelines #2: REVERSAL OF OR MANAGEMENT OF BLEEDING WITH ANTICOAGULANTS Origination Date: Revision Date: Reviewed Date: 09/12 09/12, 01/13, 11/13, 11/15
More informationGuidelines for the Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults
Guidelines for the Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults Purpose: To be used as a common tool for all practitioners involved in the care of patients
More informationEmergent Anticoagulation Reversal
U N C M E D I C A L C E N T E R G U I D E L I N E Emergent Anticoagulation Reversal I. PURPOSE: The purpose of these instructions is to provide guidelines for the reversal of or management of bleeding
More informationReversal of Anticoagulants at UCDMC
Reversal of Anticoagulants at UCDMC Introduction: Bleeding complications are a common concern with the use of anticoagulant agents. In selected situations, reversing or neutralizing the effects of an anticoagulant
More informationUse of Anticoagulant Reversal Agents
Use of Anticoagulant Reversal Agents Lori Shutter, MD shutterla@upmc.edu Vice Chair of Education Director, Neurocritical Care Program Professor, Critical Care Medicine, Neurology & Neurosurgery University
More informationUse of Prothrombin Complex Concentrates (PCC) CONTENTS
CONTENTS Page 1: Exclusion Criteria and Approved Indications for Use Page 2: Dosing / Administration / Storage Page 4: Prescribing / Monitoring / Dispensing Page 5: Cautions / Warnings / Cost Analysis
More informationReversal Agents for Anticoagulants Understanding the Options. Katisha Vance, MD, FACP Alabama Oncology January 28, 2017
Reversal Agents for Anticoagulants Understanding the Options Katisha Vance, MD, FACP Alabama Oncology January 28, 2017 Objectives Appropriately recommend reversal agents for Vitamin K antagonists Appropriately
More informationChapter 1 The Reversing Agents
Available Strategies to Reverse Anticoagulant Medications Michael L. Smith, Pharm. D., BCPS, CACP East Region Pharmacy Clinical Manager Hartford HealthCare Objectives: Describe the pharmacological agents
More informationDEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
More information3/25/2016. Objectives for Pharmacists. Stop the Bleeding! New Reversal Agents. Objectives for Pharmacy Technicians. Assessment Pre-test
Objectives for Pharmacists Stop the Bleeding! New Reversal Agents Gary D Peksa, Pharm.D., BCPS Clinical Pharmacy Specialist, Emergency Medicine Rush University Medical Center Review current strategies
More informationPost-procedure dose ok after hours. 12 hours (q 24h dosing only) assuming surgical hemostasis; second dose 24 hours after first dose.
Medication Time to wait after last dose Post-procedure dose ok after hours Can pull catheter hours after last dose Can give next dose hours after pulling catheter Enoxaparin (Lovenox) Prophylactic dose
More informationGuidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban
Guidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban Purpose The aim of this guidance is to outline the management of patients presenting
More informationANTICOAGULATION RELATED BLEEDING - GUIDELINE SUMMARY
ANTICOAGULATION RELATED BLEEDING - GUIDELINE SUMMARY Click here for the full Thrombosis Prevention Investigation and Management of Anticoagulation Guideline Click on the appropriate link below: o START
More informationLeading the Charge in Anticoagulation Reversal: Benefits, Risks, and Key Factors in Application to the Traumatically Injured Patient
Leading the Charge in Anticoagulation Reversal: Benefits, Risks, and Key Factors in Application to the Traumatically Injured Patient Emily Hutchison, PharmD BCPS Clinical Pharmacy Specialist, Trauma/Adult
More informationNanik Hatsakorzian Pharm.D/MPH
Pharm.D/MPH 2014 1 Therapeutics FDA indication & Dosing Clinical Pearls Anticoagulants Heparin Antiphospholipid antibody syndrome Cerebral thromboembolism Prosthetic heart valve Acute coronary syndrome
More information3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?
Abigail E. Miller, PharmD, BCPS Clinical Specialist, Cardiology University of North Carolina Hospitals I have no personal financial relationships with the manufacturers of the products to disclose. Boehringer
More informationAgent Dose MoA/PK/Admin Adverse events Disadvantages Protamine Heparin: 1mg neutralizes ~ 100 units Heparin neutralization in ~ 5 min
Nanik (Nayri) Hatsakorzian Pharm.D/MPH candidate 2014 Touro University College of Pharmacy CA Bleeding Reversal Agents Agent Dose MoA/PK/Admin Adverse events Disadvantages Protamine Heparin: 1mg neutralizes
More informationThis quiz is being published on behalf of the Education Committee of the SNACC.
Shobana Rajan, M.D. Staff Anesthesiologist, Cleveland Clinic, Cleveland, Ohio Quiz team; Shaheen Shaikh, M.D; Suneeta Gollapudy,M.D; Verghese Cherian, M.D This quiz is being published on behalf of the
More informationProthrombin Complex Concentrate- Octaplex. Octaplex
Prothrombin Complex Concentrate- Concentrated Factors Prothrombin Complex Concentrate (PCC) 3- factor (factor II, IX, X) 4-factor (factors II, VII, IX, X) Activated 4-factor (factors II, VIIa, IX, X) Coagulation
More informationAppendix 3 PCC Warfarin Reversal
Appendix 3 PCC Warfarin Reversal Reversal of Warfarin and Analogues 1. Principle of Procedure Guidelines for the Reversal of Oral-anticoagulation in the Event of Life Threatening Haemorrhage Prothrombin
More informationREVERSAL STRATEGIES FOR ORAL ANTICOAGULATION
REVERSAL STRATEGIES FOR ORAL ANTICOAGULATION Wesley R. Zemrak, Pharm.D., BCPS Clinical Pharmacy Specialist, Anticoagulation Maine Medical Center, Portland, ME zemraw@mmc.org 1 OBJECTIVES 1. Discuss the
More informationMANAGEMENT OF OVER-ANTICOAGULATION. Tammy K. Chung, Pharm.D. Critical Care & Cardiology Specialist Presbyterian Hospital Dallas
MANAGEMENT OF OVER-ANTICOAGULATION Tammy K. Chung, Pharm.D. Critical Care & Cardiology Specialist Presbyterian Hospital Dallas Risk of Intracranial Hemorrhage in Outpatients (From Management of Oral Anticoagulant
More informationManaging Bleeding in the Patient on DOACs
Managing Bleeding in the Patient on DOACs Spring 2016 Jean M. Connors, MD Anticoagulation Management Services BWH/DFCI Hemostatic Antithrombotic Stewardship BWH Assistant Professor of Medicine, HMS Conflicts
More informationAppendix 2H - SECONDARY CARE CONVERSION GUIDELINES ORAL ANTICOAGULANTS
Appendix 2H - SECONDARY CARE CONVERSION GUIDELINES ORAL ANTICOAGULANTS Please note that newer oral anticoagulants e.g. rivaroxaban, dabigatran and apixiban should be only be considered in patients with
More informationIntroduction. Blood Pressure
Introduction Spontaneous intracerebral hemorrhage (ICH) is a major cause of morbidity and mortality worldwide [1]. Of a number of factors that have been linked to ICH (e.g., higher rates in Asians and
More informationPlatelet-fibrin clot. 50Kd STEMI. Abciximab. Video of a IIb/IIIa inhibitor in action. Unstable Angina and non-stsegment
Objectives IIb/IIIa, Vitamin K, and Direct Thrombin Inhibition in Cardiology Michael Gulseth, Pharm. D., BCPS Assistant Professor, Duluth Pharmacy 6122 February 14, 2005 Describe the pharmacology, kinetics,
More informationa. A pharmacist may order a baseline SCr per protocol
UNITYPOINT HEALTH - MARSHALLTOWN Marshalltown, Iowa PHARMACY POLICY AND PROCEDURE Subject: Anticoagulant Therapy Per Practice Protocol (Formerly Anticoagulant therapy #NPSG.03.05.01) Inpatient Warfarin
More informationReversal of Novel Oral Anticoagulants. Angelina The, MD March 22, 2016
Reversal of Novel Oral Anticoagulants Angelina The, MD March 22, 2016 Argatroban Bivalirudin Enoxaparin Lepirudin Heparin Dabigatran Apixaban 1939 1954 1998 2000 1999 2001 10/2010 7/2011 12/2012 1/2015
More informationBlood Thinner Agent. Done by: Meznah Al-mutairi Pharm.D Candidate PNU Collage of Pharmacy
Blood Thinner Agent Done by: Meznah Al-mutairi Pharm.D Candidate PNU Collage of Pharmacy Outline: Blood thinner agent definition. anticoagulants drugs. Thrombolytics. Blood thinner agent Therapeutic interference
More informationNew Oral Anticoagulants
New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Services What percentage of time do patients on warfarin spend in therapeutic
More informationNOACS/DOACS*: COAGULATION TESTS
NOACS/DOACS*: COAGULATION TESTS OBJECTIVES: To describe the effect of the newer direct oral anticoagulants (DOACs) on laboratory coagulation tests which are widely available: prothrombin time (PT), international
More informationAnticoagulation Reversal and Treatment Strategies in Major Bleeding: Update 2016
Review Article in Major Bleeding: Update 2016 Steve Christos, DO, MS* Robin Naples, MD * Presence Resurrection Medical Center, Department of Emergency Medicine, Chicago, Illinois Lewis Katz School of Medicine
More informationDirect Oral Anticoagulants An Update
Oct. 26, 2017 Direct Oral Anticoagulants An Update Kathleen Heintz, DO, FACC Assistant Professor of Medicine Cooper Heart Institute Direct Oral Anticoagulants: DISCLAIMERS No Conflicts of Interest So what
More informationIschemic and hemorrhagic strokes in the context of the direct acting oral anticoagulants
Ischemic and hemorrhagic strokes in the context of the direct acting oral anticoagulants Van Hellerslia, PharmD, BCPS, CACP Clinical Assistant Professor Temple University School of Pharmacy Over 4 million
More informationNew Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel)
New Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel) Limitations and Advantages of UFH and LMWH Biological limitations of UFH : 1. immune-mediated
More informationManaging Hemorrhagic Complications of Non-Vitamin K Antagonist Oral Anticoagulants
Managing Hemorrhagic Complications of Non-Vitamin K Antagonist Oral Anticoagulants MICHAEL E. MULLINS MD FAACT FACEP Washington University School Of Medicine Chair, BJH Anticoagulation Subcommittee Chair,
More informationNew Age Anticoagulants: Bleeding Considerations
Ontario Regional Blood Coordinating Network March 23, 2012 New Age Anticoagulants: Bleeding Considerations Bill Geerts, MD, FRCPC Thromboembolism Specialist, Sunnybrook HSC Professor of Medicine, University
More information2.5 Other Hematology Consult:
The Warfarin Order Sheet has been approved by the P & T committee to be implemented by pharmacists. These orders are not used to treat patients with serious hemorrhagic complications. WARFARIN TARGET INR
More informationNew Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY
New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY Fact VTE is deadly! It nibbles after it bites! The 30-day mortality rates for first-time DVT or
More informationWMC PHARMACY ANTICOAGULATION PROTOCOL Current Revision: July 2017 GENERAL ORDER PROCESSING AND MANAGEMENT
WMC PHARMACY ANTICOAGULATION PROTOCOL Current Revision: July 2017 GENERAL ORDER PROCESSING AND MANAGEMENT - Entering orders for anticoagulation in Cerner Providers will enter individual orders (oneoffs)
More informationAnticoagulants: Agents, Pharmacology and Reversal
Anticoagulants: Agents, Pharmacology and Reversal Lori B Heller, M.D. Cardiac Anesthesiology Swedish Heart and Vascular Institute Medical Director, Swedish Blood Management Clinical Instructor, University
More information>>FAST TRACK<< Hemostasis has three key components: platelets, the plasma coagulation. cascade, and the blood vessel wall (endothelium).
How to Reverse an Antithrombotic Agent The authors review options and precautions to consider when you need to restore hemostasis in a patient receiving an anticoagulant, antiplatelet, or fibrinolytic
More information10 Key Things the Vascular Community Should Know about the DOACs Heather Gornik, MD, RVT, RPVI
10 Key Things the Vascular Community Should Know about the DOACs Heather Gornik, MD, RVT, RPVI Cleveland Clinic Heart and Vascular Institute Heather L. Gornik, MD has the following relationships to disclose:
More informationAdvances in Anticoagulation
May 18, 2017 Advances in Anticoagulation Wei Ling Lau, MD Assistant Professor, Nephrology University of California, Irvine Talk Outline High stroke risk in CKD population Warfarin off-target effects on
More informationAsif Serajian DO FACC FSCAI
Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac
More informationUpdate on Oral Anticoagulants. Dr. Miten R. Patel Cancer Specialists of North Florida Cell
Update on Oral Anticoagulants Dr. Miten R. Patel Cancer Specialists of North Florida Cell 904-451-9820 Email miten.patel@csnf.us Overview Highlights of the 4 new approved oral anticoagulants Results from
More informationChallenges in Coagulation
Challenges in Coagulation Michael H. Rosove, MD Clinical Professor of Medicine UCLA Division of Hematology-Oncology April 30, 2016 Vitamin K Deficiency Vitamin K1 source from diet Vitamin K2 source from
More informationAnticoagulation Management Around Endoscopy: GI Perspective. Nathan Landesman, DO FACOI Flint Gastroenterology Associates October 11, 2017
Anticoagulation Management Around Endoscopy: GI Perspective Nathan Landesman, DO FACOI Flint Gastroenterology Associates October 11, 2017 EDUCATIONAL OBJECTIVES Understand risks of holding anticoagulation
More informationAntiplatelets and Anticoagulants. Helen Leung, PharmD PGY1 Pharmacy Resident Memorial Hermann-Texas Medical Center
Antiplatelets and Anticoagulants Helen Leung, PharmD PGY1 Pharmacy Resident Memorial Hermann-Texas Medical Center Mechanism 2 http://www.medicinehack.com/2011/07/virchows-triad.html Mechanism 3 http://drtedwilliams.net/kb/index.php?pagename=coagulation%20cascade
More informationGuideline for Reversal of Antithrombotics in Intracranial Hemorrhage
Neurocrit Care (2016) 24:6 46 DOI 10.1007/s12028-015-0222-x REVIEW ARTICLE Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage A Statement for Healthcare Professionals from the Neurocritical
More informationManaging Bleeding on NOACs
Managing Bleeding on NOACs and Other Evolving ED Protocols Objectives Understand that NOACs are widely used in clinical practice Discuss the new and evolving protocols for managing bleeding in patients
More informationNovel Anticoagulant Drugs. by: Dr. M. Kamandi Fellowship of hematology and Oncology
Novel Anticoagulant Drugs by: Dr. M. Kamandi Fellowship of hematology and Oncology A-Novel Oral Anticoagulants A drug that is: safe and effective has predictable pharmacology has few drug drug and drug
More informationHemostasis and Blood Forming Organs
Hemostasis and Blood Forming Organs Subcommittee: Williams, Patricia B. (Chair) pbwillia@umich.edu McMillan, David dcmcmillan@unmc.edu Dobrydneva, Yuliya dobrydy@evms.edu DEFEROXAMINE FERROUS SULFATE ferrous
More informationStolling en anesthesie. Erik Vandermeulen MD, PhD Dept. of Anesthesia
Stolling en anesthesie Erik Vandermeulen MD, PhD Dept. of Anesthesia Preoperative use of anticoagulation Vitamin K-antagonists (VKA) Fenprocoumon (Marcoumar ) Warfarin (Marevan ) Acenocoumarol (Sintrom
More informationIntrinsic + Common = aptt. Extrinsic + Common = PT. Common Pathway
Anticoagulant Cases 12 11 Intrinsic + Common = aptt 9 8 10 7 4 Extrinsic + Common = PT 5 2 Common Pathway 1 Xa Inhibitors rivaroxaban (Xarelto) apixaban (Eliquis) edoxaban (Savaysa) What is true regarding
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Acute lung injury (ALI) transfusion-related, 363 372. See also Transfusion-related acute lung injury (TRALI) ALI. See Acute lung injury
More informationUPDATE OF NEUROCRITICAL CARE PHARMACOTHERAPY. Vera Wilson, PharmD, BCPS Emergency Services Clinical Pharmacy Specialist Johnson City Medical Center
UPDATE OF NEUROCRITICAL CARE PHARMACOTHERAPY Vera Wilson, PharmD, BCPS Emergency Services Clinical Pharmacy Specialist Johnson City Medical Center DISCLOSURE STATEMENT OF FINANCIAL INTEREST I, Vera Wilson,
More informationAnticoagulation Overview Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita
Anticoagulation Overview 2018 Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita The ideal lecture is like a miniskirt. Short enough to get
More informationPatients presenting with acute stroke while on DOACs
Patients presenting with acute stroke while on DOACs Vemmos Kostas, MD, PhD Stroke Medicine Hellenic Cardiovascular Research Society Conflicts of interest Honoraria and speaker fees from: BAYER, SANOFI,
More informationEmergent Reversal of Oral Anticoagulation: Review of Current Treatment Strategies
AACN Advanced Critical Care Volume 25, Number 1, pp. 5-12 2014 AACN ECG Challenges Earnest Alexander, PharmD, and Gregory M. Susla, PharmD Department Editors Emergent Reversal of Oral Anticoagulation:
More informationUnderstanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism. Rajat Deo, MD, MTR
Understanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism Rajat Deo, MD, MTR Director of Translational Research in Cardiac Arrhythmias Division of Cardiovascular Medicine
More informationUpdate on Antithrombotic Therapy in Acute Coronary Syndrome
Update on Antithrombotic Therapy in Acute Coronary Syndrome Laura Tsang November 13, 2006 Objectives: By the end of this session, you should understand: The role of antithrombotics in ACS Their mechanisms
More informationClinical issues which drug for which patient
Anticoagulants - a matter of heart! Towards a bright future? Clinical issues which drug for which patient Sabine Eichinger Dept. of Medicine I Medical University of Vienna/Austria Conflicts of interest
More informationOral Factor Xa Inhibitors and Clinical Laboratory Monitoring
Oral Factor Xa Inhibitors and Clinical Laboratory Monitoring MELISSA L. WHITE ABSTRACT Oral anticoagulation therapy is currently undergoing great changes with the development and use of several new medications.
More informationKCS Congress: Impact through collaboration
Stroke Prevention in Atrial Fibrillation (SPAF) in Kenya Elijah N. Ogola FACC University of Nairobi Kenya Cardiac Society Annual Scientific Congress Mombasa 28 th June 1 st July 2017 KCS Congress: Impact
More informationTargeting a Network Anticoagulation Issue. Anthony J. Macchiavelli, M.D., FHM
Targeting a Network Anticoagulation Issue Anthony J. Macchiavelli, M.D., FHM Disclosure Statement Janssen - Speaker Bureau Nonbranded Janssen research MARINER Janssen research MERCURY PE Portola research
More informationReversal of direct oral anticoagulants in the patient with GI bleeding. Marc Carrier
Reversal of direct oral anticoagulants in the patient with GI bleeding Marc Carrier Disclosure Faculty: Dr. Marc Carrier Relationships with commercial interests: Grants/Research Support: Leo Pharma, Bristol
More informationAtrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015
Atrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015 Christopher E. Bauer, MD, FACC, FHRS SSM Health Heart & Vascular Care Clinical Cardiac Electrophysiology
More informationMANAGEMENT OF OVERANTICOAGULATION AND PREOPERATIVE MANAGEMENT OF WARFARIN DOSE 1. GUIDELINES FOR THE MANAGEMENT OF AN ELEVATED INR
MANAGEMENT OF OVERANTICOAGULATION AND PREOPERATIVE MANAGEMENT OF WARFARIN DOSE 1. GUIDELINES FOR THE MANAGEMENT OF AN ELEVATED INR 1.1 Time to lower INR Prothrombinex-VF - 15 minutes Fresh Frozen Plasma
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationClinical Guideline for Anticoagulation in VTE
Clinical Guideline for Anticoagulation in VTE These clinical guidelines are intended to provide evidence-based recommendations regarding the anticoagulation in patients with DVT and PE. Please note that
More informationUpdates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism
Disclosures Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism No financial conflicts of interest Member of the ABIM Focused- Practice in Hospital Medicine Self Examination Process
More informationEmergency Management of Patients on Direct Oral Anticoagulants (DOACs)
Emergency Management of Patients on Direct Oral Anticoagulants (DOACs) Dr Tina Biss Consultant Haematologist Newcastle upon Tyne Hospitals NHS Foundation Trust NE RTC Annual Education Symposium 11 th October
More informationBMS Project ID: 432US /16
The Bristol-Myers Squibb/Pfizer Medical Alliance would like to inform you that the following sections of the prescribing information for ELIQUIS (apixaban) have been updated and the underlined text denotes
More informationHeparin-Induced Thrombocytopenia (HIT)
Heparin-Induced Thrombocytopenia (HIT) Joshua Ononuju, Pharm. D. Owensboro Medical Health Systems Objectives Overview Pathogenesis Risk factors Clinical Presentation and Diagnosis Treatment goals and options
More informationDo s and Don t of DOACs DISCLOSURE
Do s and Don t of DOACs Tom DeLoughery, MD MACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant/Research none Content Expert: Elsevier
More informationDr Tina Biss Consultant Haematologist Newcastle Hospitals NHS Foundation Trust. North East RTC Annual Education Symposium 16 th October 2014
Dr Tina Biss Consultant Haematologist Newcastle Hospitals NHS Foundation Trust North East RTC Annual Education Symposium 16 th October 2014 The extent of the problem 1-2% of the UK population are anticoagulated
More informationA Cascade of Updates: Hot Topics in Anticoagulation
A Cascade of Updates: Hot Topics in Anticoagulation Heather A. Powell, PharmD, BCPS Assistant Professor of Clinical Sciences Roosevelt University College of Pharmacy Golden L. Peters, PharmD, BCPS Associate
More information10/24/2013. Heparin-Induced Thrombocytopenia (HIT) Anticoagulation Management in ECMO Therapy:
Anticoagulation Management in ECMO Therapy: Heparin-Induced (HIT) Michael H. Creer, MD Professor of Pathology Director, Clinical Laboratories, Medical Co- Director, Hematopathology and Chief, Division
More informationRazvana Akbar Anticoagulation Pharmacist LTH
Razvana Akbar Anticoagulation Pharmacist LTH Platelet function Drugs affecting Coagulation; Anti-platelet drugs Anticoagulants Oral anticoagulants Parenteral anticoagulants Drugs affecting Haemoglobin
More informationPage 1 of 6. Low 1 (score 0-3) Monitor platelets and signs and symptoms of thrombosis and continue heparin
Page 1 of 6 Estimate probability of HIT using the Four T s 1 Low 1 (score 0-3) Intermediate 1 (score 4-5) or High 1 (score 6-8) Monitor platelets and signs and symptoms of thrombosis and continue heparin
More informationHEPARIN-INDUCED THROMBOCYTOPENIA (HIT)
HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) OBJECTIVE: To assist clinicians with the investigation and management of suspected and documented heparin-induced thrombocytopenia (HIT). BACKGROUND: HIT is a transient,
More informationEndoscopy and the Anticoagulated Patient
Endoscopy and the Anticoagulated Patient John R. Saltzman MD, FACG Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School Objectives To accurately assess the risk
More informationVENOUS THROMBOEMBOLISM PHARMACOLOGY. University of Hawai i Hilo DNP Program NURS 603 Advanced Clinical Pharmacology Danita Narciso Pharm D
VENOUS THROMBOEMBOLISM PHARMACOLOGY University of Hawai i Hilo DNP Program NURS 603 Advanced Clinical Pharmacology Danita Narciso Pharm D LEARNING OBJECTIVES Know what factors anticoagulant medications
More informationReducing the Use of Reversal Agents in a Community Hospital
4//0 Objectives Reducing the Use of Reversal Agents in a Community Hospital Maria Paulina Duarte, PharmD PGY- Pharmacy Resident Mercy Hospital, A Campus of Plantation General Hospital Review the appropriate
More informationMANAGEMENT OF BLEEDING AND EXCESSIVE ANTICOAGULATION IN ADULTS RECEIVING ANTI-COAGULANTS
Hairmyres Hospital MANAGEMENT OF BLEEDING AND EXCESSIVE ANTICOAGULATION IN ADULTS RECEIVING ANTI-COAGULANTS Bleeding in patients on anticoagulants, even in the absence of over-anticoagulation, can be life-threatening
More informationUpdates in Coagulation Thrombophilia testing and direct oral anticoagulants. Kevin Y. Chen, MD Hematology and Medical Oncology October 13, 2017
Updates in Coagulation Thrombophilia testing and direct oral anticoagulants Kevin Y. Chen, MD Hematology and Medical Oncology October 13, 2017 No conflicts of interest Introduction to thrombosis Hemostasis
More informationChoosing and Managing Direct Oral Anticoagulants (DOACs)
Choosing and Managing Direct Oral Anticoagulants (DOACs) Ana G. Antun, MD, MSc Assistant Professor, Department of Hematology and Medical Oncology Winship Cancer Institute of Emory University 1 Outline
More informationDebate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF
Debate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF Bradley P. Knight, MD Director of Cardiac Electrophysiology Bluhm Cardiovascular Institute Northwestern
More informationFaculty. DOACs and Reversal Agents: Disclosures. Considerations for Health-System Pharmacists. Learning Objectives
Faculty DOACs and Reversal Agents: Considerations for Health-System Pharmacists Mark A. Munger, PharmD, FCCP, FACC, FHFSA Professor of Pharmacotherapy Adjunct Professor, Internal Medicine University of
More informationOutpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015
Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015 General Principles: There is compelling data in the medical literature to support
More informationTHROMBOTIC DISORDERS: The Final Frontier
THROMBOTIC DISORDERS: The Final Frontier Jeffrey I. Weitz, MD, FRCP(C), FACP Professor of Medicine and Biochemistry McMaster University Canada Research Chair in Thrombosis Heart & Stroke Foundation/ J.F.
More informationGuidelines for Anticoagulation in Paediatric Cardiac Patients
Leeds Children s Hospital Guidelines for Anticoagulation in Paediatric Cardiac Patients SURGICAL PATIENTS Preoperative Management Blalock-Taussig (BT) Shunt / Fontan circulation / Sano Shunt and Severe
More informationAnticoagulation Drug Therapy: A Review
Review Article Katherine Harter, MD Michael Levine, MD Sean O. Henderson, MD University of Southern California, LA+USC Medical Center, Department of Emergency Medicine, Los Angeles, California Supervising
More informationUPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS
UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS Armando Mansilha MD, PhD, FEBVS 16 th National Congress of the Italian Society of Vascular and Endovascular Surgery Bologna, 2017 Disclosure I have the following
More informationNew Oral Blood Thinners and New Dilemmas: What Do We Need To Know?
New Oral Blood Thinners and New Dilemmas: What Do We Need To Know? Richard Mullvain RPH BCPS (AQC) Essentia Health Heart & Vascular Conference May 18 th, 2012 Objectives: Review and understand the pharmacodynamics
More informationTreatment Options and How They Work
Treatment Options and How They Work Robin Offord Director of Clinical Pharmacy UCL Hospitals NHS Foundation Trust robin.offord@uclh.nhs.uk Introducing the term anticoagulant... What they do Inhibit the
More information